Therapeutic Effects of Chiglitazar and Rosa Roxburghii in Patients with Metabolic Syndrome
Study Overview
This study aimed to assess how effective Chiglitazar, when combined with Rosa roxburghii Tratt (RRT), is for inpatients with psychiatric disorders suffering from antipsychotic-induced metabolic syndrome (MetS). A total of 100 patients participated, split into two groups: one receiving only Chiglitazar and the other receiving Chiglitazar with RRT.
Key Findings
- Improvement in Measurements: Both groups showed significant reductions in waist circumference and improvements in lipid profiles and glucose metabolism over 12 weeks.
- Better Results with RRT: The group receiving Chiglitazar + RRT had greater improvements in lipid levels, with notable decreases in triglycerides and total cholesterol.
- Reduced Inflammation: Inflammatory markers decreased significantly in both groups, with the Chiglitazar + RRT group showing consistently lower levels at 8 and 12 weeks.
- Improved Psychiatric Symptoms: The Chiglitazar + RRT group had a significantly lower PANSS score at 12 weeks, indicating better management of psychiatric symptoms.
Conclusion
Combining Chiglitazar with RRT effectively improves metabolic health, reduces inflammation, and enhances psychiatric well-being in patients with antipsychotic-induced MetS.
Enhancing Clinical Practices
Clinical trials are essential for developing safe and effective treatments. To maximize their benefits in everyday practice, we introduce DocSym, an AI-driven platform that consolidates ICD-11 standards, clinical protocols, and research into a single, easy-to-use resource for healthcare providers.
Practical Solutions for Healthcare
- Streamlined Operations: Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, making patient care management more efficient.
- Improved Workflows: By leveraging AI, clinics can enhance their workflows, improve patient outcomes, and reduce reliance on paper processes.
Discover how we can assist your practice by visiting aidevmd.com.